Table 5.
Top 10 over-represented pathway interactions enriched for interactions between mutated genes in brain cancer in mixPCN (ranked by increasing p-values of mutated gene pairs).
| pathway A | pathway B | mutationa(allb) |
|---|---|---|
| the co-stimulatory signal during T-cell activation | regulation of cell cycle progression by plk3 | 1(1) |
| ctcf: first multivalent nuclear factor | cell cycle: G1/s check point | 4(33) |
| proteogylcan syndecan-mediated signalling events | role of brca1 brca2 and atr in cancer susceptibility | 4(49) |
| BARD1 signalling events | proteogylcan syndecan-mediated signalling events | 4(112) |
| proteogylcan syndecan-mediated signalling events | cell cycle: G2/m checkpoint | 4(125) |
| BARD1 signalling events | EGFR-dependent endothelin signalling events | 3(44) |
| proteogylcan syndecan-mediated signalling events | regulation of transcriptional activity by pml | 3(66) |
| regulation of telomerase | p53 signalling pathway | 3(68) |
| syndecan-1-mediated signalling events | regulation of cell cycle progression by plk3 | 3(76) |
| androgen-mediated signalling | role of brca1 brca2 and atr in cancer susceptibility | 3(77) |
aNumber of interactions between mutated genes in brain cancer existing between pathways A and B.
bNumber of all gene interactions existing between pathways A and B.